1
|
Avenoso D, Mehra V, Slonim LB, de Farias M, Alshehri H, Bouziana S, Krishnamurthy P, Kulasekararaj A, Dazzi F, Wood H, Kenyon M, Leung YT, Anteh S, Shah MN, Hannah G, Serpenti F, Gameil A, Bourlon C, Dragoi OD, Pagliuca A, Potter V. Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Transplant Cell Ther 2023; 29:698.e1-698.e6. [PMID: 37579918 DOI: 10.1016/j.jtct.2023.08.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Revised: 07/27/2023] [Accepted: 08/08/2023] [Indexed: 08/16/2023]
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative strategy for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The prediction of transplantation-related mortality (TRM) using the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score and an arbitrary upper age limit of 55 years for administering myeloablative conditioning (MAC) are common strategies to ensure a safe procedure. The use of reduced-toxicity conditioning regimens is an additional approach to providing safe and effective myeloablation. Herein we report the outcome of AML and MDS patients conditioned with fludarabine and a myeloablative dose of busulfan (FB4) stratified by age and HCT-CI score. The primary objective was overall survival (OS) for patients age ≥55 years. Secondary objectives were total OS, TRM, graft-versus-host disease (GVHD), and GVHD, relapse-free survival (GRFS). The 2 year OS was 72% in patients age <55 and 51% in patients age ≥55. In patients age ≥55 with an HCT-CI <2, the estimated 2 year OS was 64%, with median OS not reached. In those with HCT-CI ≥2, the 2-year OS was 43%, with a median OS of 14 months. The total cumulative incidence of relapse was 30% regardless of age or HCT-CI score. FB4 conditioning regimen offers a high rate of prolonged remission with a relapse rate similar to that reported in previous studies. These positive outcomes suggest that this conditioning platform can be offered to patients age ≥55 years in the absence of comorbidities, and that age should not be the sole determinant of conditioning intensity.
Collapse
Affiliation(s)
- Daniele Avenoso
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom.
| | - Varun Mehra
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Liron Barnea Slonim
- King's College Hospital NHS Foundation Trust, Department of Histopathology, Denmark Hill, London, United Kingdom
| | - Madson de Farias
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Hassan Alshehri
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Styliani Bouziana
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Pramila Krishnamurthy
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Austin Kulasekararaj
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Francesco Dazzi
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Henry Wood
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Michelle Kenyon
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Ye Ting Leung
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Sandra Anteh
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Mili Naresh Shah
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Guy Hannah
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Fabio Serpenti
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Amna Gameil
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Christianne Bourlon
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Oana Diana Dragoi
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Antonio Pagliuca
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| | - Victoria Potter
- King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, United Kingdom
| |
Collapse
|
2
|
Liu Z, Wang C, Wang Y, Wang L, Zhang Y, Yan G. 4'-O-Methylbroussochalcone B as a novel tubulin polymerization inhibitor suppressed the proliferation and migration of acute myeloid leukaemia cells. BMC Cancer 2021; 21:91. [PMID: 33482772 PMCID: PMC7825173 DOI: 10.1186/s12885-020-07759-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Accepted: 12/22/2020] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Recent years, survival rates of human with high-risk acute myeloid leukaemia (AML) have not raised substantially. This research aimed to investigate the role of 4'-O-Methylbroussochalcone B, for the treatment of human AML. METHODS Firstly, we evaluated the effects of six chalcones on AML cells activity by MTT assay. Immunofluorescence staining, tubulin polymerization assay and N,N'-ethylenebis (iodoacetamide) (EBI) competition assay were performed on ML-2 cells. Transwell and apoptosis assay were also utilized in ML-2 cells and OCI-AML5 cells. The expressions of migration-related proteins, apoptosis-related proteins and Wnt/β-catenin pathway were detected by Western Blot. RESULTS The results found six chalcones exhibited the anti-proliferative activity against different AML cell lines. Based on the results of immunofluorescence staining, tubulin polymerization assay and EBI competition assay, 4'-O-Methylbroussochalcone B was discovered to be a novel colchicine site tubulin polymerization inhibitor. 4'-O-Methylbroussochalcone B could induce apoptosis, inhibit proliferation and migration of ML-2 cells and OCI-AML5 cells. The cells were arrested in the G2-M phase by the treatment of 4'-O-Methylbroussochalcone B. In addition, 4'-O-Methylbroussochalcone B regulated MAPK and Wnt/β-catenin pathways in AML cells. CONCLUSION 4'-O-Methylbroussochalcone B might inhibit proliferation and migration of the AML cells by MAPK and Wnt/β-catenin pathways as a tubulin polymerization inhibitor. It is promising for 4'-O-Methylbroussochalcone B to become a new drug to treat AML.
Collapse
Affiliation(s)
- Ziying Liu
- Department of pediatrics, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, China
| | - Changshui Wang
- Department of Clinical & Translational Medicine, Jining Life Science Center, Jining, China
| | - Yali Wang
- Department of Clinical & Translational Medicine, Jining Life Science Center, Jining, China
| | - Lei Wang
- Department of Clinical & Translational Medicine, Jining Life Science Center, Jining, China
| | - Yueyuan Zhang
- Department of Clinical & Translational Medicine, Jining Life Science Center, Jining, China
| | - Genquan Yan
- Department of pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
| |
Collapse
|
3
|
Abstract
Cancer is a leading cause of mortality and morbidity worldwide. Despite major improvements in current therapeutic methods, ideal therapeutic strategies for improved tumor elimination are still lacking. Recently, immunotherapy has attracted much attention, and many immune-active agents have been approved for clinical use alone or in combination with other cancer drugs. However, some patients have a poor response to these agents. New agents and strategies are needed to overcome such deficiencies. Phosphatidylserine (PS) is an essential component of bilayer cell membranes and is normally present in the inner leaflet. In the physiological state, PS exposure on the external leaflet not only acts as an engulfment signal for phagocytosis in apoptotic cells but also participates in blood coagulation, myoblast fusion and immune regulation in nonapoptotic cells. In the tumor microenvironment, PS exposure is significantly increased on the surface of tumor cells or tumor cell-derived microvesicles, which have innate immunosuppressive properties and facilitate tumor growth and metastasis. To date, agents targeting PS have been developed, some of which are under investigation in clinical trials as combination drugs for various cancers. However, controversial results are emerging in laboratory research as well as in clinical trials, and the efficiency of PS-targeting agents remains uncertain. In this review, we summarize recent progress in our understanding of the physiological and pathological roles of PS, with a focus on immune suppressive features. In addition, we discuss current drug developments that are based on PS-targeting strategies in both experimental and clinical studies. We hope to provide a future research direction for the development of new agents for cancer therapy.
Collapse
Affiliation(s)
- Wenguang Chang
- Institute for Translational Medicine, The Affiliated Hospital, College of medicine, Qingdao University, Qingdao, China
| | - Hongge Fa
- Institute for Translational Medicine, The Affiliated Hospital, College of medicine, Qingdao University, Qingdao, China
- School of Basic Medical Sciences, College of medicine, Qingdao University, Qingdao, China
| | - Dandan Xiao
- Institute for Translational Medicine, The Affiliated Hospital, College of medicine, Qingdao University, Qingdao, China
- School of Basic Medical Sciences, College of medicine, Qingdao University, Qingdao, China
| | - Jianxun Wang
- School of Basic Medical Sciences, College of medicine, Qingdao University, Qingdao, China
| |
Collapse
|